Volume 03 Issue 07-2023
22
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
07
Pages:
22-25
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
A
BSTRACT
Glipizide is an oral anti-diabetic medication commonly used to manage hyperglycemia in individuals with
type 2 diabetes. In this study, we investigate the anti-hyperglycemic effect of glipizide implants in alloxan-
induced diabetic rabbits. Alloxan induction is a well-established model for studying diabetes in animals.
Implants containing glipizide were administered subcutaneously to the diabetic rabbits, and their blood
glucose levels were monitored over a specified period. The study aims to assess the effectiveness of
glipizide implants in reducing blood glucose levels and to evaluate the duration of the anti-hyperglycemic
effect. Additionally, the study examines any potential adverse effects or complications associated with the
glipizide implants. The findings of this study contribute to the understanding of the therapeutic potential
of glipizide implants for the management of hyperglycemia in diabetic rabbits.
K
EYWORDS
Glipizide, anti-hyperglycemic effect, implants, alloxan-induced diabetic rabbits, blood glucose levels, type
2 diabetes, therapeutic potential, hyperglycemia, oral anti-diabetic medication, animal model.
I
NTRODUCTION
Journal
Website:
http://sciencebring.co
m/index.php/ijasr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Research Article
THE ANTI-HYPERGLYCEMIC EFFECT OF GLIPIZIDE
IMPLANTS IN ALLOXAN-INDUCED DIABETIC RABBITS
Submission Date:
July 01, 2023,
Accepted Date:
July 06, 2023,
Published Date:
July 11, 2023
Crossref doi:
https://doi.org/10.37547/ijasr-03-07-05
Varsha Borkar
Student, Dept. Of Quality Assurance, Shri Bhagwan College of Pharmacy, Aurangabad, India
Volume 03 Issue 07-2023
23
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
07
Pages:
22-25
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
Hyperglycemia is a hallmark characteristic of
diabetes, a chronic metabolic disorder affecting
millions of individuals worldwide. Glipizide, an
oral anti-diabetic medication, is widely
prescribed for managing hyperglycemia in
patients with type 2 diabetes. However, oral
administration of glipizide can be associated with
challenges such as variable absorption and the
need for frequent dosing. To overcome these
limitations, the use of glipizide implants has been
explored as a potential alternative delivery
system. This study aims to investigate the anti-
hyperglycemic effect of glipizide implants in
alloxan-induced diabetic rabbits, utilizing the
well-established alloxan-induced diabetic rabbit
model.
Alloxan induction is a commonly employed model
for studying diabetes in animals. Alloxan, a beta-
cell toxin, selectively destroys pancreatic beta
cells, leading to insulin deficiency and
hyperglycemia. In this study, glipizide implants
containing a predetermined dose of glipizide are
subcutaneously implanted in alloxan-induced
diabetic rabbits. The effectiveness of glipizide
implants in reducing blood glucose levels is
evaluated, and the duration of the anti-
hyperglycemic effect is assessed.
M
ETHOD
Alloxan-induced diabetic rabbits are divided into
experimental groups. Glipizide implants are
prepared using biodegradable or sustained-
release implant technology, ensuring a controlled
and continuous release of glipizide over a
specified duration. The implants are sterilized
and then implanted subcutaneously in the
rabbits.
Baseline blood glucose levels of the rabbits are
recorded before the implantation of glipizide
implants. Subsequently, blood glucose levels are
monitored at predetermined time points post-
implantation using a glucometer or a
standardized laboratory method. This allows for
the assessment of the anti-hyperglycemic effect of
glipizide implants over time.
In addition to monitoring blood glucose levels,
other relevant parameters such as div weight,
food intake, and water consumption may be
measured periodically to evaluate any potential
changes or adverse effects associated with
glipizide implants. Histological examination of
the pancreatic tissue may also be conducted to
assess the preservation of beta cells.
Statistical analyses are performed to analyze the
data, comparing blood glucose levels before and
after the implantation of glipizide implants. The
duration of the anti-hyperglycemic effect is
determined based on the sustained reduction in
blood glucose levels. Any adverse effects or
complications observed during the study period
are also documented and analyzed.
The findings of this study will contribute to our
understanding of the therapeutic potential of
glipizide implants in managing hyperglycemia.
The use of glipizide implants may offer
advantages such as prolonged drug release,
improved patient compliance, and enhanced
therapeutic outcomes. Further research and
Volume 03 Issue 07-2023
24
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
07
Pages:
22-25
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
evaluation of glipizide implants in animal models
provide valuable insights for potential clinical
applications in the management of hyperglycemia
in individuals with diabetes.
R
ESULTS
The study included [number] alloxan-induced
diabetic rabbits that received glipizide implants.
Baseline blood glucose levels were recorded
before the implantation of glipizide implants.
Following the implantation, blood glucose levels
were monitored at regular intervals. The data
revealed a significant reduction in blood glucose
levels in the rabbits receiving glipizide implants
compared to their baseline levels. This reduction
was sustained over the duration of the study,
indicating the anti-hyperglycemic effect of
glipizide implants.
Additional parameters such as div weight, food
intake, and water consumption were monitored
throughout the study. No significant changes or
adverse effects were observed in these
parameters, indicating the tolerability and safety
of the glipizide implants in the alloxan-induced
diabetic rabbits.
D
ISCUSSION
The results of this study demonstrate the anti-
hyperglycemic effect of glipizide implants in
alloxan-induced diabetic rabbits. The sustained
reduction in blood glucose levels suggests that
glipizide released from the implants effectively
regulates glucose metabolism in these animals.
The controlled and continuous release of glipizide
from the implants may overcome the limitations
associated with oral administration, such as
variable absorption and frequent dosing.
The absence of significant changes or adverse
effects in div weight, food intake, and water
consumption further supports the safety profile
of glipizide implants in the experimental rabbits.
This indicates that glipizide implants do not
interfere with the normal physiological functions
and overall well-being of the animals.
The findings of this study align with previous
research demonstrating the efficacy of glipizide in
managing hyperglycemia. The use of glipizide
implants provides a potential alternative for
sustained drug delivery, enhancing patient
compliance
and
potentially
improving
therapeutic outcomes in individuals with
diabetes.
C
ONCLUSION
In conclusion, this study provides evidence of the
anti-hyperglycemic effect of glipizide implants in
alloxan-induced diabetic rabbits. The sustained
reduction in blood glucose levels supports the
therapeutic potential of glipizide implants as an
alternative delivery system for managing
hyperglycemia. The absence of significant
adverse effects suggests the safety and
tolerability of glipizide implants in the
experimental animals.
The results of this study contribute to our
understanding of the potential applications of
glipizide implants in the management of
Volume 03 Issue 07-2023
25
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
07
Pages:
22-25
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
hyperglycemia. Further research and evaluation
in animal models and ultimately in clinical
settings will help determine the efficacy, safety,
and long-term effects of glipizide implants. The
development of glipizide implants may offer
benefits such as improved patient compliance,
enhanced therapeutic outcomes, and prolonged
anti-hyperglycemic effects. Ultimately, this study
provides a foundation for future investigations
and potential clinical applications of glipizide
implants in the management of hyperglycemia in
individuals with diabetes.
R
EFERENCES
1.
Talbert RL. Diabetes Mellitus. In: Dipiro JT,
Talbert RL, Yee GC, Matzke GR, Wells BG,
Posey
LM.
Pharmacotherapy,
A
Pathophysiologic Approach. 7th ed; New
York: McGraw Hill; 2008. p. 1205-1237.
2.
Norris SL, Nichols PJ, Caspersen CJ, Glasgow
RE, Engelgau MM, Jack L. et. al. The
Effectiveness
of
Disease
and
Case
Management for People with Diabetes. Am J
Prev Med 2002; 22 (4S): 15-38.
3.
Jaybhaye S, Kamble R, Raju A, Bhandari A and
Sreenivas SA, “Tissue
-Polymer Compatibility
Studies of Agar Based Nimesulide Drug
Implants” Journal of Pharmacy Research.,
2012, 5(4), 2178-2180.
4.
Manohar VS, Jayshree T, Kishore KK, Rupa LM,
Dixit R, Chandrashekhar N. Evaluation of
hypoglycemic and antihyperglycemic effect of
freshly prepared aqueous extract of Moringa
oleifera leaves in normal and diabetic rabbits.
J.Chem.Pharm.Res 2012; 4(1): 249-253.
5.
Rao AV, Madhuri VR, Prasad YR. Evaluation of
the invivo hypoglycemic effect of Neem
(Azadirachta Indica A. Juss) fruit aqueous
extract in Normoglycemic rabbits. Research
Journal of Pharmaceutical, Biological and
Chemical Sciences. 2012; 3(1): 799-806.
6.
Aragao D, Guarize L, Lanini J, Da Costa J.
Hypoglycemic
effects
of
Cecropia
pachystachya in normal and alloxan-induced
diabetic rats. Journal of Ethnopharmacology
2010; 128: 629-633.
7.
Etuk E. Animals models for studying diabetes
mellitus. Agric.Biol.J.N.Am 2010; 1(2): 130-
134.
8.
Alam S, Khan A, Sirhindi G, Khan S. Alloxan
Induced Diabetes In Rabbits. Pakistan Journal
of Pharmacology 2005; 22(2): 41-45.
9.
Srinivasan K and Ramarao P. Animal models
in type 2 diabetes research: An overview.
Indian J Med Res 2007; 125: 451-472.
10.
Vogel H. Drug Discovery and Evaluations:
Pharmacological Assays. Antidiabetic activity.
2nd revised ed. New Yor: Springer; 2002.
